Item 1.01. Entry into a Material Definitive Agreement.
On April 15, 2021, XOMA (US) LLC ("XOMA"), a wholly-owned subsidiary of XOMA
Corporation (the "Company"), entered into a contractual arrangement with Affimed
N.V. ("Affimed") and affiliated entities (the Agreement"). The Agreement
provides for payments to XOMA on potential future commercial sales related to
the three innate cell engager (ICE®) molecules and any pre-loaded natural killer
(NK) cells containing the ICE® molecules. Additionally, under the Agreement,
XOMA is eligible to receive a potential milestone for each program, upon each
candidate receiving marketing approval.
The description of the Agreement contained herein does not purport to be
complete and is qualified in its entirety by reference to the copy of the
Agreement which will be filed as an exhibit to the Company's Quarterly Report on
Form 10-Q for the period ending June 30, 2021.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses